Login to Your Account



Singapore's Aslan readies for Taiwan listing, capital raise for cancer pipeline

By Christopher Horton
Contributing Writer

Wednesday, February 8, 2017

HONG KONG – With five drugs in its pipeline and a deal with big pharma worth tens of millions of dollars, Singapore drug developer Aslan Pharmaceuticals Pte Ltd. aims to tap the markets in Taiwan, looking to overcome some flagging investor sentiment on biopharma.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription